Topical Cyproterone Acetate Treatment in Women With Acne

Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial.

OBJECTIVE To evaluate the clinical and hormonal response of topically applied cyproterone acetate, oral cyproterone acetate, and placebo lotion in women with acne. DESIGN Placebo-controlled, randomized study. SETTING Patients were recruited from the Institute of Endocrine Cosmetics, Vienna, Austria. PATIENTS Forty women with acne. INTERVENTIONS Treatment with oral medication consisting ...

Cyproterone acetate in treatment of precocious puberty.

Twenty-nine children (23 girls, 6 boys) with precocious puberty were treated with cyproterone acetate for various periods of time ranging from 6 months to 3 years 4 months. They received an oral dose ranging from 70-150 mg/m2 per day, or an intramuscular depot injection once a fortnight or once a month at a dose ranging from 107-230 mg/m2. Both forms of therapy were found to suppress the signs ...

Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment.

Since the recent introduction of a drug regimen containing 2 mg of the antiandrogen cyproterone acetate and 50 micrograms ethinyl-oestradiol (Diane; oestrogen-cyproterone acetate) several uncontrolled reports have extolled the benefits of this drug. Double blind studies, however, are lacking. Sixty two patients with moderate or moderately severe acne were therefore included in a double blind tr...

New Topical Acne Treatment

Comparison of Spironolactone plus Cyproterone Acetate plus Cyproterone Compound with Spironolactone plus Cyproterone Compound in Hirsutism: A randomized clinical trial

Background: Monotherapy is not usually effective in the treatment of hirsutism. Objective: Comparison of 2 therapeutic regimens in the treatment of hirsutism. Patients and methods: In this open parallel controlled clinical trial, 101 Patients suffering from hirsutism were randomly divided into two equal groups. 50 patients were treated with spironolactone (50 mg/day) plus cyproterone comp...